The global celiac disease treatment market is estimated to be USD 0.654 billion in 2024 and is expected to reach USD 2.24 billion by 2035, with a CAGR of 11.84% during the forecast period 2025-2035. Increased awareness and early diagnosis of celiac disease, advancement in treatment options, the rise of the market for gluten-free foods, and government support and initiatives will all contribute to the market's expansion.
In February 2024, the FDA approved Xolair (omalizumab), developed by Novartis, as the first and only medication for reducing allergic reactions in individuals aged one and older with IgE-mediated food allergies. This milestone marks a significant advancement in the treatment of food allergies, particularly for those with severe and potentially life-threatening reactions. The approval was based on the successful Phase III OUtMATCH trial, which demonstrated Xolair's ability to enhance tolerance to small amounts of allergens, including peanuts and milk. This discovery possibly improves patient outcomes and quality of life by providing patients and healthcare providers with an efficient tool to control food allergies through the expansion of therapy alternatives.
By treatment, the vitamins and minerals segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the increasing awareness of the importance of nutritional supplementation in managing celiac disease and the growing demand for products that address nutrient deficiencies common in affected individuals. For instance, The first-in-human Phase I trial of VTP-1000 in adults with celiac disease was reported in September 2024 by Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical business creating innovative immunotherapeutic candidates that direct T cells to treat illness. Additionally, the gluten-free diets segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of celiac disease, growing awareness of the importance of a gluten-free diet for disease management, and the increasing availability of gluten-free food options.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the convenience, ease of use, and patient preference for oral treatments, as well as the growing availability of oral supplements that help manage nutrient deficiencies. For instance, Topas Therapeutics launched a Phase IIa clinical trial of TPM502 in May 2023 to treat the autoimmune condition celiac disease. The multicenter, randomized, double-blind, placebo-controlled trial will assess the pharmacodynamic effects, safety, and tolerability of two dose-escalating TPM502 administrations in cohorts. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to its ability to provide more direct and rapid therapeutic effects, especially for patients with severe symptoms or those who require intensive management.
By distribution channel, the hospital's segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the concentrated healthcare services provided in hospitals, the availability of specialized treatments, and the higher number of celiac disease patients seeking care in such settings. For instance, in May 2023, Anokion reported encouraging findings from a Phase I trial that looked at KAN-101 as a celiac disease treatment. The ACeD experiment examined gluten-free diets in two cohorts of single-ascending dose and multi-ascending dose persons with celiac disease. It was a randomized, double-blind, placebo-controlled study. Additionally, the research centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on clinical trials, ongoing research to discover new treatments, and the pivotal role of research centers in advancing the understanding and management of celiac disease.
The North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of celiac disease, advanced healthcare infrastructure, increased awareness of the condition, and the presence of key pharmaceutical players offering innovative treatment options. For instance, First Wave BioPharma announced in March 2024 that it had acquired ImmunogenX in an all-stock deal. The combined company's goal is to advance a GI pipeline that includes several late-stage clinical assets, such as latiglutenase, a targeted oral biotherapeutic for celiac disease that may be the first of its kind and is almost ready for Phase III. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising diagnosis rates of celiac disease, growing healthcare access, improving awareness, and the increasing adoption of gluten-free diets in countries like Japan, China, and India.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
In February 2024, the FDA approved Xolair (omalizumab), developed by Novartis, as the first and only medication for reducing allergic reactions in individuals aged one and older with IgE-mediated food allergies. This milestone marks a significant advancement in the treatment of food allergies, particularly for those with severe and potentially life-threatening reactions. The approval was based on the successful Phase III OUtMATCH trial, which demonstrated Xolair's ability to enhance tolerance to small amounts of allergens, including peanuts and milk. This discovery possibly improves patient outcomes and quality of life by providing patients and healthcare providers with an efficient tool to control food allergies through the expansion of therapy alternatives.
By treatment, the vitamins and minerals segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the increasing awareness of the importance of nutritional supplementation in managing celiac disease and the growing demand for products that address nutrient deficiencies common in affected individuals. For instance, The first-in-human Phase I trial of VTP-1000 in adults with celiac disease was reported in September 2024 by Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical business creating innovative immunotherapeutic candidates that direct T cells to treat illness. Additionally, the gluten-free diets segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of celiac disease, growing awareness of the importance of a gluten-free diet for disease management, and the increasing availability of gluten-free food options.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the convenience, ease of use, and patient preference for oral treatments, as well as the growing availability of oral supplements that help manage nutrient deficiencies. For instance, Topas Therapeutics launched a Phase IIa clinical trial of TPM502 in May 2023 to treat the autoimmune condition celiac disease. The multicenter, randomized, double-blind, placebo-controlled trial will assess the pharmacodynamic effects, safety, and tolerability of two dose-escalating TPM502 administrations in cohorts. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to its ability to provide more direct and rapid therapeutic effects, especially for patients with severe symptoms or those who require intensive management.
By distribution channel, the hospital's segment accounted for the highest revenue-grossing segment in the global celiac disease treatment market in 2024 owing to the concentrated healthcare services provided in hospitals, the availability of specialized treatments, and the higher number of celiac disease patients seeking care in such settings. For instance, in May 2023, Anokion reported encouraging findings from a Phase I trial that looked at KAN-101 as a celiac disease treatment. The ACeD experiment examined gluten-free diets in two cohorts of single-ascending dose and multi-ascending dose persons with celiac disease. It was a randomized, double-blind, placebo-controlled study. Additionally, the research centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on clinical trials, ongoing research to discover new treatments, and the pivotal role of research centers in advancing the understanding and management of celiac disease.
The North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of celiac disease, advanced healthcare infrastructure, increased awareness of the condition, and the presence of key pharmaceutical players offering innovative treatment options. For instance, First Wave BioPharma announced in March 2024 that it had acquired ImmunogenX in an all-stock deal. The combined company's goal is to advance a GI pipeline that includes several late-stage clinical assets, such as latiglutenase, a targeted oral biotherapeutic for celiac disease that may be the first of its kind and is almost ready for Phase III. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising diagnosis rates of celiac disease, growing healthcare access, improving awareness, and the increasing adoption of gluten-free diets in countries like Japan, China, and India.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Treatment, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Celiac Disease Treatment Market Report 2024 - 2035
Celiac Disease Treatment Market Analysis & Forecast by Treatment 2024 - 2035 (Revenue USD Bn)
- Vitamins & Minerals
- Gluten-free Diet
- Medical Therapies
- Infliximab
- Larazotide Acetate
- Azathioprine
- Budesonide
- Others
Celiac Disease Treatment Market Analysis & Forecast by Route of Administration 2024 - 2035 (Revenue USD Bn)
- Oral
- Parenteral
Celiac Disease Treatment Market Analysis & Forecast by Distribution Channel 2024 - 2035 (Revenue USD Bn)
- Hospitals
- Research Centers
- Others
Celiac Disease Treatment Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Celiac Disease Treatment Market: Treatment Estimates & Trend Analysis
8. Celiac Disease Treatment Market: Route of Administration Estimates & Trend Analysis
9. Celiac Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Celiac Disease Treatment Market
12. Europe Global Celiac Disease Treatment Market
13. Asia Pacific Global Celiac Disease Treatment Market
14. Latin America Global Celiac Disease Treatment Market
15. MEA Global Celiac Disease Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Entero Therapeutics, Inc.
- Novartis AG
- Takeda Pharmaceutical Company
- AbbVie Inc.
- Biogen Inc.
- ImmunogenX
- Provention Bio, Inc.
- Gluten Free Trading Co.
- Alba Therapeutics
- Merck & Co., Inc.
- Theravance Biopharma
- Celimmune LLC
- ImmusanT, Inc.
- Sanofi
- ZyVersa Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.65 Billion |
| Forecasted Market Value ( USD | $ 2.24 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
